Neural Repair Strategies for Parkinson's Disease: Insights from Primate Models

Nonhuman primate models of Parkinson's disease (PD) have been invaluable to our understanding of the human disease and in the advancement of novel therapies for its treatment. In this review, we attempt to give a brief overview of the animal models of PD currently used, with a more comprehensive focus on the advantages and disadvantages presented by their use in the nonhuman primate. In particular, discussion addresses the 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydopyridine (MPTP), rotenone, paraquat, and maneb parkinsonian models. Additionally, the role of primate PD models in the development of novel therapies, such as trophic factor delivery, grafting, and deep brain stimulation, are described. Finally, the contribution of primate PD models to our understanding of the etiology and pathology of human PD is discussed.

[1]  Vladimir N. Uversky,et al.  Neurotoxicant-induced animal models of Parkinson’s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration , 2004, Cell and Tissue Research.

[2]  D. Jacobowitz,et al.  Transient behavioral recovery in hemiparkinsonian primates after adrenal medullary allografts. , 1988, Progress in brain research.

[3]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[4]  J. P. Huston,et al.  UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.

[5]  L. Olson,et al.  Electrophysiology and cytology of hippocampal formation transplants in the anterior chamber of the eye. II. Cholinergic mechanisms , 1977, Brain Research.

[6]  S. Dunnett,et al.  6-Hydroxydopamine Lesions of Nigrostriatal Neurons as an Animal Model of Parkinson’s Disease , 1994 .

[7]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[8]  M. Chesselet,et al.  Variable effects of chronic subcutaneous administration of rotenone on striatal histology , 2004, The Journal of comparative neurology.

[9]  J Q Trojanowski,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[10]  W. Longstreth,et al.  Pesticides and risk of Parkinson disease: a population-based case-control study. , 2005, Archives of neurology.

[11]  T. Ljungberg,et al.  Electrophysiological and cytological studies of brain homografts in the anterior chamber of the eye: maturation of cerebellar cortex in oculo. , 1974, Brain research.

[12]  J. Sagen,et al.  Robust survival of isolated bovine adrenal chromaffin cells following intrastriatal transplantation: a novel hypothesis of adrenal graft viability , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  O. Hornykiewicz,et al.  The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease , 1988, Neuroscience Letters.

[14]  D. Eidelberg,et al.  Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. , 2001, Human gene therapy.

[15]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[16]  Cheryl D. DiCarlo,et al.  Behavioral and immunohistochemical effects of chronic intravenous and subcutaneous infusions of varying doses of rotenone , 2004, Experimental Neurology.

[17]  Y. Iris Chen,et al.  Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model , 2003, NeuroImage.

[18]  A. Benabid,et al.  Bilateral subthalamic nucleus stimulation for severe Parkinson's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.

[19]  A. Kupsch,et al.  Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline , 2001, Journal of Neural Transmission.

[20]  Stanley Fahn,et al.  Dyskinesia after fetal cell transplantation for parkinsonism: A PET study , 2002, Annals of neurology.

[21]  A. Benabid,et al.  Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.

[22]  Haruhiko Kishima,et al.  Functional Recovery in a Primate Model of Parkinson's Disease following Motor Cortex Stimulation , 2004, Neuron.

[23]  M. Polymeropoulos,et al.  Genetics of Parkinson's disease. , 1997, Human molecular genetics.

[24]  A. Björklund,et al.  Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path , 1976, Nature.

[25]  R. Ridley,et al.  A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions , 2004, Experimental Brain Research.

[26]  G. Wooten,et al.  Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons , 1993, Brain Research.

[27]  R. Penn,et al.  Putative chromaffin cell survival and enhanced host‐derived TH‐Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease , 1991, Annals of neurology.

[28]  H. Wang,et al.  Study of adrenal medullary tissue transplantation to striatum in parkinsonism. , 1988, Progress in brain research.

[29]  R. Roth,et al.  Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus) , 1997, Neuroscience.

[30]  S. Gill,et al.  Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.

[31]  D. D. Di Monte,et al.  Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model , 2000, Movement disorders : official journal of the Movement Disorder Society.

[32]  I. Miyazaki,et al.  Rotenone induces aggregation of γ-tubulin protein and subsequent disorganization of the centrosome: Relevance to formation of inclusion bodies and neurodegeneration , 2005, Neuroscience.

[33]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[34]  N. Déglon,et al.  Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease , 2004, Neurobiology of Disease.

[35]  P. Follesa,et al.  Topographical localization of glial cell line-derived neurotrophic factor in the human brain stem: an immunohistochemical study of prenatal, neonatal and adult brains , 2002, Journal of Chemical Neuroanatomy.

[36]  H. Bergman,et al.  The primate subthalamic nucleus. I. Functional properties in intact animals. , 1994, Journal of neurophysiology.

[37]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[38]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[39]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[40]  C. Sachs,et al.  Mechanisms of action of 6-hydroxydopamine. , 1975, Biochemical Pharmacology.

[41]  U. Ungerstedt,et al.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.

[42]  A. Björklund,et al.  Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. , 2002, Brain research. Developmental brain research.

[43]  M. Muenter,et al.  Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature , 2001, Movement disorders : official journal of the Movement Disorder Society.

[44]  E. Richfield,et al.  Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? , 2000, Brain Research.

[45]  B Bioulac,et al.  Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[46]  S. Dunnett,et al.  Long-Term Survival of Human Central Nervous System Progenitor Cells Transplanted into a Rat Model of Parkinson's Disease , 1997, Experimental Neurology.

[47]  R. Bakay,et al.  Biochemical and Behavioral Correction of MPTP Parkinson‐like Syndrome by Fetal Cell Transplantation a , 1987, Annals of the New York Academy of Sciences.

[48]  E. Oldfield,et al.  Long-term evaluation of hemiparkinsonian monkeys after adrenal autografting or cavitation alone. , 1990, Journal of neurosurgery.

[49]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[51]  M. Mishkin,et al.  Adrènal medulla grafts survice and exhibit catecholamine-specific fluorescence in the primate brain , 1984, Experimental Neurology.

[52]  R. Penn,et al.  The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. , 1988, Neurosurgery.

[53]  R. Ridley,et al.  Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus) , 2003, Experimental Neurology.

[54]  Joseph Jankovic,et al.  Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations , 2005, Movement disorders : official journal of the Movement Disorder Society.

[55]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[56]  E. Tiffany-Castiglioni,et al.  The Bipyridyl Herbicide Paraquat Produces Oxidative Stress-Mediated Toxicity in Human Neuroblastoma SH-SY5Y Cells: Relevance to the Dopaminergic Pathogenesis , 2005, Journal of toxicology and environmental health. Part A.

[57]  J. Deniau,et al.  Spontaneous and Evoked Activity of Substantia Nigra Pars Reticulata Neurons during High-Frequency Stimulation of the Subthalamic Nucleus , 2003, The Journal of Neuroscience.

[58]  G. Nikkhah,et al.  Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model , 1994, Brain Research.

[59]  C. Marsden,et al.  Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. , 2000, Brain : a journal of neurology.

[60]  L. Olson,et al.  Early prenatal ontogeny of central monoamine neurons in the rat: Fluorescence histochemical observations , 2004, Zeitschrift für Anatomie und Entwicklungsgeschichte.

[61]  D. Cory-Slechta,et al.  Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. , 2005, Neurotoxicology.

[62]  K. Mewes,et al.  The Subthalamic Nucleus and Tremor in Parkinson's Disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[63]  R. Roth,et al.  Intrastriatal grafts from multiple donors do not result in a proportional increase in survival of dopamine neurons in nonhuman primates. , 1998, Cell transplantation.

[64]  A. Albanese,et al.  Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates , 1993, Neuroscience.

[65]  R. Roth,et al.  Sham surgery does not ameliorate MPTP-induced behavioral deficits in monkeys. , 1995, Cell transplantation.

[66]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[67]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[68]  S. Haber,et al.  Transplantation of fetal dopamine neurons in primate brain reverses MPTP induced parkinsonism. , 1987, Progress in brain research.

[69]  P. Calabresi,et al.  Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism , 2005, Neuroscience.

[70]  R. Roth,et al.  Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment , 1999, Neuroscience.

[71]  J. Vitek,et al.  Stimulation of the Subthalamic Nucleus Changes the Firing Pattern of Pallidal Neurons , 2003, The Journal of Neuroscience.

[72]  Nobuyuki Itoh,et al.  Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. , 2005, The Journal of clinical investigation.

[73]  R. Roth,et al.  Cryopreservation, culture, and transplantation of human fetal mesencephalic tissue into monkeys. , 1988, Science.

[74]  H. Shibasaki,et al.  Immunohistochemical localization of glial cell line-derived neurotrophic factor in the human central nervous system , 2000, Neuroscience.

[75]  W. Tatton,et al.  Etiology and pathogenesis of Parkinson's disease. , 1999, Annual review of neuroscience.

[76]  Philippe Hantraye,et al.  MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons , 2000, Neuroreport.

[77]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[78]  J. Eberling,et al.  Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. , 2003, Frontiers in bioscience : a journal and virtual library.

[79]  R. Penn,et al.  Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. , 1989, The New England journal of medicine.

[80]  G. Gerhardt,et al.  Increased dopamine clearance in the non-lesioned striatum of rhesus monkeys with unilateral 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) striatal lesions , 1995, Neuroscience Letters.

[81]  P. Jenner,et al.  The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. , 2003, Parkinsonism & related disorders.

[82]  Andisheh Eslamboli.  Marmoset monkey models of Parkinson's disease: Which model, when and why? , 2005, Brain Research Bulletin.

[83]  E. Oldfield,et al.  Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. , 1994, Journal of neurosurgery.

[84]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Kordower,et al.  Adrenal medullary tissue grafting in Parkinson's disease. , 1988, Journal of neurosurgery.

[86]  J. Kordower,et al.  Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates , 2006, Gene Therapy.

[87]  R. Barker,et al.  Survival of Nigral Grafts within the Striatum of Marmosets with 6-Ohda Lesions Depends Critically on Donor Embryo Age , 1997 .

[88]  D. Hansel,et al.  Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. , 2005, Brain : a journal of neurology.

[89]  A L Benabid,et al.  Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation , 1998, Movement disorders : official journal of the Movement Disorder Society.

[90]  Y. Mitsumoto,et al.  Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. , 1998, Biochemical and biophysical research communications.

[91]  Gary W Miller,et al.  Paraquat neurotoxicity is distinct from that of MPTP and rotenone. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[92]  R. Ridley,et al.  Behavioral Assessment of the Effects of Embryonic Nigral Grafts in Marmosets with Unilateral 6-OHDA Lesions of the Nigrostriatal Pathway , 1994, Experimental Neurology.

[93]  G. Nikkhah,et al.  A microtransplantation approach for cell suspension grafting in the rat parkinson model: A detailed account of the methodology , 1994, Neuroscience.

[94]  L. Tremblay,et al.  Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP‐treated monkeys , 2003, The European journal of neuroscience.

[95]  T. Montine,et al.  Manganese ethylene‐bis‐dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction , 2003, Journal of neurochemistry.

[96]  W. Schultz.  MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology. , 1988, General pharmacology.

[97]  M. Boscaro,et al.  Pharmacologic Management , 2005 .

[98]  C. Olanow,et al.  Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. , 1999, Archives of neurology.

[99]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[100]  R. Ridley,et al.  Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson’s disease in marmoset monkeys , 2003, Experimental Neurology.

[101]  A. Bjo¨rklund,et al.  Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival , 1976, Brain Research.

[102]  G. Petzinger,et al.  The parkinsonian toxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP): a technical review of its utility and safety , 2001, Journal of neurochemistry.

[103]  K. Mohanakumar,et al.  Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease , 2005, Brain Research.

[104]  R. Barker,et al.  Survival of nigral grafts within the striatum of marmosets with 6-OHDA lesions depends critically on donor embryo age. , 1997, Cell transplantation.

[105]  O. Lindvall,et al.  Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen , 1987, Annals of neurology.

[106]  G. Sedvall,et al.  Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. , 1985, Journal of neurosurgery.

[107]  C. Marsden,et al.  Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.

[108]  R. Roth,et al.  Fetal Dopamine Cell Survival after Transplantation Is Dramatically Improved at a Critical Donor Gestational Age in Nonhuman Primates , 1993, Experimental Neurology.

[109]  P. Sanberg,et al.  Neural transplantation for treatment of Parkinson's disease. , 2002, Drug discovery today.

[110]  Todd Sherer,et al.  Rotenone Model of Parkinson Disease , 2005, Journal of Biological Chemistry.

[111]  T. Aziz,et al.  Lesioning the Subthalamic Nucleus in the Treatment of Parkinson’s Disease , 2002, Stereotactic and Functional Neurosurgery.

[112]  R. Roth,et al.  Intrastriatal Grafts from Multiple Donors do not Result in a Proportional Increase in Survival of Dopamine Neurons in Nonhuman Primates , 1998 .

[113]  W. Langston,et al.  α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates , 2005, Neurobiology of Disease.

[114]  A. Akaike,et al.  FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. , 2000, Biochemical and biophysical research communications.

[115]  Clive N Svendsen,et al.  A new method for the rapid and long term growth of human neural precursor cells , 1998, Journal of Neuroscience Methods.

[116]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[117]  E. Richfield,et al.  A Fetal Risk Factor for Parkinson’s Disease , 2004, Developmental Neuroscience.